Finally, SGLT2 inhibitors are of benefit in arrhythmias and particularly AF, with a meta-analysis by Mariani et al. [132] indicating that dapagliflozin reduced the risk for AF in both the overall general population and patients with diabetes. The gene discussed is SLC5A2; the disease is Arrhythmia.